Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30564441 | 1.00 | KMT2A (0.51) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL30092486 | 1.00 | KMT2A (0.51) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL242521 | 1.00 | KMT2A (0.51) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL26008763 | 0.90 | MDM4 (0.49) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL25357928 | 0.88 | MDM4 (0.60) | KMT2ACASP3MDM4TP53MDM2 | |
| SCHEMBL5839367 | 0.88 | KMT2A (0.52) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL10187006 | 0.88 | KMT2A (0.52) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL21639432 | 0.88 | MDM4 (0.60) | KMT2ACASP3MDM4TP53MDM2 | |
| SCHEMBL7391110 | 0.88 | KMT2A (0.52) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL18191950 | 0.88 | MDM4 (0.60) | KMT2ACASP3MDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022143-A1 | Cyclic Peptide Inhibitors of IL-23 | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-22 | — | — | US | disclosed |
| US-20260000659-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12478617-B2 | Lipidated peptide inhibitors of interleukin-23 receptor | JANSSEN BIOTECH, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| EP-4554671-A1 | CYCLIC PEPTIDE INHIBITORS OF IL-23 | JANSSEN Pharmaceutica NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| US-20240409598-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2024-12-12 | — | — | US | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240173309-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-30 | — | — | US | disclosed |
| EP-4370146-A2 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Janssen Biotech, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3315499-A1 | CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-9174998-B2 | (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-11-03 | — | — | US | disclosed |
| US-9174998-B2 | (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-11-03 | — | — | US | disclosed |
| WO-2015098853-A1 | (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2015-07-02 | — | — | WO | disclosed |
| US-20150175615-A1 | (6S,9aS)-N-Benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-(methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound | PRISM PHARMA CO., LTD. (JP) | 2015-06-25 | — | — | US | disclosed |
| US-20150175615-A1 | (6S,9aS)-N-Benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-(methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound | PRISM PHARMA CO., LTD. (JP) | 2015-06-25 | — | — | US | disclosed |
| US-8748412-B2 | Phenylalanine derivatives and their use as non-peptide GLP-1 receptor modulators | ARGUSINA BIOSCIENCE INC. (KY) | 2014-06-10 | — | — | US | disclosed |
| EP-2531198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | Argusina Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120004198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011097300-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022143-A1 | Cyclic Peptide Inhibitors of IL-23 | IL23R, IL17A, IL36G | KMT2A 958/4885CASP3 160/4885MDM4 4631/4885 |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | KMT2A 2979/4885CASP3 4173/4885MDM4 1740/4885 |
| US-20240173309-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL36G | KMT2A 3658/4885CASP3 268/4885MDM4 4576/4885 |
| US-20120004198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, GPR119 | KMT2A 2731/4885CASP3 4145/4885MDM4 4749/4885 |
| US-20260000659-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL36G, IL15RA | KMT2A 3239/4885CASP3 157/4885MDM4 3782/4885 |
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL17A | KMT2A 3912/4885CASP3 213/4885MDM4 4869/4885 |
| US-12478617-B2 | Lipidated peptide inhibitors of interleukin-23 receptor | IL23R, IL1RN, IL36G | KMT2A 3658/4885CASP3 268/4885MDM4 4576/4885 |
| US-20240409598-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL36G | KMT2A 3676/4885CASP3 582/4885MDM4 3300/4885 |
| US-20150175615-A1 | (6S,9aS)-N-Benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-(methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound | WNT1, WNT3A, WNT3 | KMT2A 1166/4885CASP3 1013/4885MDM4 4278/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | KMT2A 3415/4885CASP3 4451/4885MDM4 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.